New Drug "Cocktails" Prove Effective Against Hepatitis

November 09, 1998

Research Also Links New Virus and Unexplained Liver Disease

CHICAGO, November 9 - At The American Association for the Study of Liver Diseases 1998 Annual Meeting in Chicago, November 6 - 10, some of the world's top biomedical researchers unveiled studies of drug therapies that are offering new hope in the fight against Hepatitis B and C. Another study examined the role of a newly discovered virus in liver disease.

HIV Drug Lamivudine Helps Hepatitis B Patients When Interferon Can't

At the AASLD Annual Meeting, Eugene Schiff, MD, University of Miami, discussed a study of the effects of a new drug, Lamivudine, that was given to chronic Hepatitis B patients who had previously failed Interferon therapy. There are many such patients, because Interferon is effective only 30%-40% of the time. Lamivudine, a drug that has been used to treat HIV patients, can be taken orally unlike Interferon, which must be injected every day. The study found that patients who took Lamivudine did much better than those who took a placebo, or who took Lamivudine in combination with Interferon. All those who took the new drug alone depressed the level of Hepatitis B virus in their bodies. Almost three quarters cleared the virus, either permanently or as long as they kept taking the drug "All in all, Lamivudine appears safe and effective," said Schiff. "In the future, I expect it will be used in combination with other drugs as part of an overall treatment of chronic Hepatitis B patients."

Interferon alfa-2b +ribavirin vs. Hepatitis C - Three Studies

Three studies on treatment of chronic Hepatitis C, reported at the AASLD Annual Meeting, found that acombination of Interferon alfa-2b and ribavirin (Rebetol) was dramatically effective. John McHutchison, MD, of Scripps Clinic and Research Foundation, reported on one study of more than 900 chronic Hepatitis C patients who had not had antiviral therapy before. Half the patients were given a daily dose of the Interferon alfa-2b and ribavirin (Rebetol) combinationfor 24 or 48 weeks, while the other half were given interferon alone.Those patients who received the combination did much better than those who didnot. According to the abstract of the research, the drug combination was "significantly more effective than Interferon alone." In addition, "This combination therapy has an acceptable safety profile."

Another study, presented at the AASLD Annual Meeting by Thierry Poynard, MD, of the Hepato Gastro Groupe Hospitale Pitie Salpetriere in Paris, examined the results of an International European trial of the Interferon alfa-2b and ribavirin combination as a treatment for chronic Hepatitis C. This study, too, found the combination to be effective. "Intron A[interferon]/Rebetol combination therapy was significantly more effective than Introl A monotherapy," according to the study abstract. "This is a huge breakthrough," says Poynard.

A third study, also presented by Poynard,unveiled the results of using the Interferon alfa-2b/ribavirin to treat liver fibrosis in Hepatitis C patients. The last stage of liver fibrosis in such patients is cirrhosis, which can be fatal. The huge study of almost 2,000 patients found that the combination of drugs reduces dramatically the rate of liver fibrosis progression. "This is now the most promising form of therapy," says Poynard. "It appears to be both effective and probably cost effective because of the reduction of cirrhosis incidence."

Possible Role of New TT-Virusin Liver Disease

Some 5% of liver disease is of unknown origin. A paper presented at the AASLD Annual meeting by Philip Adjei, Mayo Clinic, examined the possible role in liver disease played by a newly discovered single-strand DNA virus, TT-virus(TTV). Researchers studied patients who had received liver transplants and who showed no evidence of any of the known causes of liver disease. The patients were monitored both for the presence of TTV and evidence of liver disease over time. After 12 months, the presence of liver disease was significantly greater among those patients whowere TTV infected than among those who were not. "This study does not by itself indicate that TTV causes liver disease,"says Adjei. "But TTV is certainly worthy of further study."
-end-
AASLD is the leading medical organization for liver researchers and physicians. Founded by physicians in 1950, AASLD's mission is to advance the science and practice of hepatology. Today, AASLD provides representation and education for more than 2,200 hepatologists worldwide.



American Association For The Study of Liver Diseases

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.